Far-infrared Therapy for Hemodialysis Patients

January 6, 2024

Abstract

Although the arteriovenous fistula is considered the best access due to low complications, it faces challenges such as poor maturation rates and patency issues. The present paper describes the current status of far-infrared therapy as a treatment modality to enhance AVF maturation and access survival. The mechanism underlying FIR therapy involves vasodilatory, angiogenesis, and the induction of vasodilation and anti-inflammatory factors. Thermal effect of FIR therapy involve upregulation of endothelial nitric oxide synthase, while non-thermal effects include reduced oxidative stress and improved endothelial function. In conclusion, FIR therapy presents potential benefits for improving vascular access flow and survival.

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
July 16, 2025
FIRAPY Medical Japan proudly participated in the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , held in Osaka from June 27 to 29, 2025 . This year marked a major milestone for FIRAPY in Japan: a total of 11 FIRAPY-related research presentations were featured during the congress—showcasing growing academic interest in far-infrared therapy as a supportive, non-invasive treatment in dialysis care. represents a significant milestone in FIRAPY’s ongoing academic engagement in dialysis-related research.
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for
July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
More Posts